Synthekine

Synthekine is a private, preclinical-stage biotech founded in 2019 and headquartered in Menlo Park, California. The company is pioneering a new class of engineered cytokine therapeutics designed to be selective, thereby aiming to unlock the full therapeutic potential of cytokines while avoiding their historical limitations of toxicity and pleiotropic effects. Its pipeline targets a broad range of cancers and autoimmune, inflammatory, and metabolic diseases. Synthekine is backed by top-tier life science investors and is led by a team with deep expertise in immunology and cytokine biology.

Two proprietary cytokine engineering modalities: 1) Cytokine Partial Agonists (engineered natural cytokines with biased signaling) and 2) Surrogate Cytokine Agonists (bispecific molecules that localize cytokine receptor activation to disease sites).

The competitive landscape is intensifying, with numerous companies (e.g., Nektar, NeoImmuneTech, Anaveon, Werewolf Therapeutics) and large pharma actively developing engineered cytokine therapies. Differentiation will depend on the clinical profile of Synthekine's candidates, particularly their therapeutic index (efficacy vs. toxicity) compared to rivals.